Drug Profile
Emtricitabine/tenofovir alafenamide - Gilead Sciences
Alternative Names: DESCOVY; Descovy; F/TAF; Tenofovir alafenamide/emtricitabineLatest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Developer Clinton Health Access Initiative; Gilead Sciences; Japan Tobacco; National Institute of Allergy and Infectious Diseases; PENTA Foundation
- Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 19 Dec 2023 University of Washington and Gilead Sciences completes a Phase-II/III clinical trials in HIV-1 infections (Prevention) in Kenya (PO) (NCT05140954)
- 13 Jul 2023 Gilead Sciences, Clinton Health Access Initiative and Penta agree to co-develop dispersible paediatric fixed dose formulation of emtricitabine/tenofovir alafenamide for HIV infections (In children)
- 13 Jul 2023 Preclinical trials in HIV-1 infections in USA (PO)